NEW DELHI: Drug firm Zydus Cadila para Friday te koikena janaishe biological therapy PegiHep covid 19 patients khan uporte phase 3 clinical trials shuru kuribole nimete Drugs Controller General of India (DCGI) para manishe.
Etu company para phase 2 clinical trials PegiHep logote juwa moina khotom kurishe.regulatory filing te Zydus Cadila para koikena janaishe tai khan para DGCI para approval paishe etu bi covid 19 patients nimete phase 3 clinical trials shuru kuribole nimete etu te biological therapy Pegylated Interferon alpha-2b or PegiHep logote.
Filing te kuwa hisaab te Etu trials kuntu toh December para shuru kurishe etu toh 250 patients khan 20 nohoile 25 centres khan india te lobole ase.
Sharvil Patel, Managing Director of Cadila Healthcare Ltd para koikena janaishe’ami khan khushi ase etu results phase 2 study Pegylated Interferon alpha 2-b para kuntu te potential dikhaishe virus titres toh komti kuribole nimete beemar nimete akhe te diya toh.
Ami khan laga kaam toh ekta bhal elach sabole nimete ase covid 19 nimete ladai kuribole karne kuntu toh safe ase aro asani para dibole nimete aro etu bi beemar laga dukh toh komti kuribole nimete.
Etu uporte company bkhan para enika nishena phase 2 trial Mexico te loi ase aro etu uporte US Food and Drug Administration (USFDA) te kaam kuri ase ekta Investigational New Drug (IND) application PegiHep nimete khulibole nimete etu bi ekta appropriate clinical trials khan shuru kuribole nimete US te.
Add Comment